Evidence for extensive pleiotropy among pharmacogenes

Pharmacogenomics. 2016 Jun;17(8):853-66. doi: 10.2217/pgs-2015-0007. Epub 2016 Jun 1.

Abstract

Aim: We sought to identify potential pleiotropy involving pharmacogenes.

Methods: We tested 184 functional variants in 34 pharmacogenes for associations using a custom grouping of International Classification and Disease, Ninth Revision billing codes extracted from deidentified electronic health records of 6892 patients.

Results: We replicated several associations including ABCG2 (rs2231142) and gout (p = 1.73 × 10(-7); odds ratio [OR]: 1.73; 95% CI: 1.40-2.12); and SLCO1B1 (rs4149056) and jaundice (p = 2.50 × 10(-4); OR: 1.67; 95% CI: 1.27-2.20).

Conclusion: In this systematic screen for phenotypic associations with functional variants, several novel genotype-phenotype combinations also achieved phenome-wide significance, including SLC15A2 rs1143672 and renal osteodystrophy (p = 2.67 × 10(-) (6); OR: 0.61; 95% CI: 0.49-0.75).

Keywords: absorption, distribution, metabolism and excretion; electronic health records; genetic association study; pharmacogenomics; phenome-wide association study.

MeSH terms

  • Adult
  • Black or African American
  • Cytochrome P-450 CYP2C19 / genetics
  • Female
  • Genetic Pleiotropy*
  • Genome-Wide Association Study
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Pharmacogenetics*
  • Phenotype
  • Symporters / genetics

Substances

  • Symporters
  • hydrogen-coupled oligopeptide transporter PepT2
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19